Tanabe Seiyaku Company, Limited

Mitsubishi Tanabe Pharma Corporation

Janssen Pharmaceutica Nv

Sumihiro Nomura

Takayuki Kawaguchi

Kenji Tsujihara

Eiji Kawanishi

Kiichiro Ueta

Toshiyuki Kume

Mikiko Tsukimoto

Ila Sircar

Hiroshi Narita

Yasushi Honma

Yasuo Sekine

Kazuaki Naito

Kenneth M Wells

Koichiro Yamada

Ahmed F Abdel-Magid

Hiroshi Iwata

Yasuo Yamamoto

Ronald K Russell

Mamoru Matsumoto

Ryuichi Ishida

Shawn T Branum

Steven Mehrman

Xun Li

Hideo Nakai

Michio Yamamura

Toshiaki Sakamoto

Lorraine Scott

Yasuhiko Sato

Derek A Beauchamp

Fan Zhang-Plasket

Mitsuya Hongu

Yosuke Matsumura

Shigeki Sakamaki

Yuichi Koga

Maureen Chislom

Maureen Chisholm

The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

Process for the preparation of compounds useful as inhibitors of SGLT-2

Process for the preparation of compounds useful as inhibitors of SGLT

A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is &#x2014;(CH)&#x2014; (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Glucopyranoside compound

A novel crystal form of 1-(&#x3b2;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.

Crystalline form of 1-(&#x3b2;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate

The present invention relates to a phenylalanine derivative of Formula (I) wherein Xis a halogen atom, Xis a halogen atom, Q is a CHR&#x2014; is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.

[object Object]

Crystalline form of 1-(&#x3b2;-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate

A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom;

Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein Ris halogen, or alkyl, Ris hydrogen, or halogen, Ar is phenyl, or thienyl, which may be substituted with halogen, alkyl, alkoxy, alkylthio, etc.

Indole derivatives

Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein Ris fluorine, or chlorine, and Ris hydrogen, or fluorine, which are SGLT inhibitors and are useful for treatment or prevention of diabetes and related conditions.

A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein &#x2014;NR&#x2014; group and &#x2014;CH&#x2014; group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter

Inhibitors of alpha4 mediated cell adhesion

Growing community of inventors

Osaka, Japan

Sumihiro Nomura